Meeting
2022 ASCO Genitourinary Cancers Symposium
Management, surveillance patterns, and costs associated with low-grade papillary (Ta) nonmuscle-invasive bladder cancer.
Authors
Kelly K. Bree
MD Anderson Cancer Center, Houston, TX
Kelly K. Bree , Yong Shan , Patrick J. Hensley , Niyati Lobo , Chengrui Hu , Douglas S. Tyler , Karim Chamie , Ashish M. Kamat , Stephen B. Williams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 464)
DOI
10.1200/JCO.2022.40.6_suppl.464
Abstract #
464
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
First Author: Edward M. Uchio
Poster
2022 ASCO Genitourinary Cancers Symposium
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
First Author: Michiel Simon Van Der Heijden
Poster
2019 Genitourinary Cancers Symposium
Association of the commensal urinary microbiome with response to Bacillus Calmette-Guérin (BCG) immunotherapy in nonmuscle invasive bladder cancer.
First Author: Randy F. Sweis
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore